StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV)

Investment analysts at StockNews.com started coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report issued to clients and investors on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating and issued a $5.00 target price on shares of Minerva Neurosciences in a research note on Wednesday, November 6th.

Minerva Neurosciences Stock Performance

Shares of NASDAQ NERV opened at $2.38 on Wednesday. The firm has a market cap of $16.64 million, a P/E ratio of -5.41 and a beta of 0.11. Minerva Neurosciences has a 1 year low of $2.03 and a 1 year high of $13.49. The firm’s 50 day moving average price is $2.23 and its 200 day moving average price is $2.54.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.